Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer

Lisa M. Hess, Setsuko K Chambers, Kenneth D Hatch, Alton Hallum, Mike F. Janicek, Joseph Buscema, Matthew Borst, Cynthia Johnson, Lisa Slayton, Yuda Chongpison, David S Alberts

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Change in cognitive function is increasingly being recognized as an adverse outcome related to chemotherapy treatment. These changes need not be severe to impact patient functional ability and quality of life. The primary goal of this study was to determine if there is evidence of changes in the cognitive function domains of attention, processing speed, and response time among women with newly diagnosed advanced ovarian cancer who receive chemotherapy. Eligible patients were women diagnosed with stage III-IV epithelial ovarian or primary peritoneal cancer who had not yet received chemotherapy but who were prescribed a minimum of six cycles (courses) of chemotherapy treatment. Cognitive function was assessed by a computerized, Web-based assessment (attention, processing speed, and reaction time) and by patient self-report. Cognitive function was assessed at three time points: prior to the first course (baseline), course three, and course six. Medical records were reviewed to abstract information on chemotherapy treatment, concomitant medications, and blood test results (eg, hemoglobin, CA-125). Of the 27 eligible participants, 92% and 86% demonstrated cognitive impairments from baseline to course three and from baseline to course six of chemotherapy, respectively. Impairment was detected in two or more cognitive domains among 48% (12 of 25) and 41% (9 of 22) of participants at course three and course six of chemotherapy, respectively. This study shows evidence of decline in cognitive function among women being treated for ovarian cancer. There is a need for additional, prospective research to better understand the impact of chemotherapy on cognitive function among ovarian cancer patients so that effective preventive and treatment strategies can be developed.

Original languageEnglish (US)
Pages (from-to)252-258
Number of pages7
JournalJournal of Supportive Oncology
Volume8
Issue number6
DOIs
StatePublished - Nov 2010

Fingerprint

Ovarian Neoplasms
Cognition
Drug Therapy
Therapeutics
Reaction Time
Aptitude
Hematologic Tests
Self Report
Medical Records
Hemoglobins
Quality of Life
Research
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. / Hess, Lisa M.; Chambers, Setsuko K; Hatch, Kenneth D; Hallum, Alton; Janicek, Mike F.; Buscema, Joseph; Borst, Matthew; Johnson, Cynthia; Slayton, Lisa; Chongpison, Yuda; Alberts, David S.

In: Journal of Supportive Oncology, Vol. 8, No. 6, 11.2010, p. 252-258.

Research output: Contribution to journalArticle

Hess, Lisa M. ; Chambers, Setsuko K ; Hatch, Kenneth D ; Hallum, Alton ; Janicek, Mike F. ; Buscema, Joseph ; Borst, Matthew ; Johnson, Cynthia ; Slayton, Lisa ; Chongpison, Yuda ; Alberts, David S. / Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. In: Journal of Supportive Oncology. 2010 ; Vol. 8, No. 6. pp. 252-258.
@article{8ef9813b39fe4a0e89d016a324f57c65,
title = "Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer",
abstract = "Change in cognitive function is increasingly being recognized as an adverse outcome related to chemotherapy treatment. These changes need not be severe to impact patient functional ability and quality of life. The primary goal of this study was to determine if there is evidence of changes in the cognitive function domains of attention, processing speed, and response time among women with newly diagnosed advanced ovarian cancer who receive chemotherapy. Eligible patients were women diagnosed with stage III-IV epithelial ovarian or primary peritoneal cancer who had not yet received chemotherapy but who were prescribed a minimum of six cycles (courses) of chemotherapy treatment. Cognitive function was assessed by a computerized, Web-based assessment (attention, processing speed, and reaction time) and by patient self-report. Cognitive function was assessed at three time points: prior to the first course (baseline), course three, and course six. Medical records were reviewed to abstract information on chemotherapy treatment, concomitant medications, and blood test results (eg, hemoglobin, CA-125). Of the 27 eligible participants, 92{\%} and 86{\%} demonstrated cognitive impairments from baseline to course three and from baseline to course six of chemotherapy, respectively. Impairment was detected in two or more cognitive domains among 48{\%} (12 of 25) and 41{\%} (9 of 22) of participants at course three and course six of chemotherapy, respectively. This study shows evidence of decline in cognitive function among women being treated for ovarian cancer. There is a need for additional, prospective research to better understand the impact of chemotherapy on cognitive function among ovarian cancer patients so that effective preventive and treatment strategies can be developed.",
author = "Hess, {Lisa M.} and Chambers, {Setsuko K} and Hatch, {Kenneth D} and Alton Hallum and Janicek, {Mike F.} and Joseph Buscema and Matthew Borst and Cynthia Johnson and Lisa Slayton and Yuda Chongpison and Alberts, {David S}",
year = "2010",
month = "11",
doi = "10.1016/j.suponc.2010.09.028",
language = "English (US)",
volume = "8",
pages = "252--258",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "6",

}

TY - JOUR

T1 - Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer

AU - Hess, Lisa M.

AU - Chambers, Setsuko K

AU - Hatch, Kenneth D

AU - Hallum, Alton

AU - Janicek, Mike F.

AU - Buscema, Joseph

AU - Borst, Matthew

AU - Johnson, Cynthia

AU - Slayton, Lisa

AU - Chongpison, Yuda

AU - Alberts, David S

PY - 2010/11

Y1 - 2010/11

N2 - Change in cognitive function is increasingly being recognized as an adverse outcome related to chemotherapy treatment. These changes need not be severe to impact patient functional ability and quality of life. The primary goal of this study was to determine if there is evidence of changes in the cognitive function domains of attention, processing speed, and response time among women with newly diagnosed advanced ovarian cancer who receive chemotherapy. Eligible patients were women diagnosed with stage III-IV epithelial ovarian or primary peritoneal cancer who had not yet received chemotherapy but who were prescribed a minimum of six cycles (courses) of chemotherapy treatment. Cognitive function was assessed by a computerized, Web-based assessment (attention, processing speed, and reaction time) and by patient self-report. Cognitive function was assessed at three time points: prior to the first course (baseline), course three, and course six. Medical records were reviewed to abstract information on chemotherapy treatment, concomitant medications, and blood test results (eg, hemoglobin, CA-125). Of the 27 eligible participants, 92% and 86% demonstrated cognitive impairments from baseline to course three and from baseline to course six of chemotherapy, respectively. Impairment was detected in two or more cognitive domains among 48% (12 of 25) and 41% (9 of 22) of participants at course three and course six of chemotherapy, respectively. This study shows evidence of decline in cognitive function among women being treated for ovarian cancer. There is a need for additional, prospective research to better understand the impact of chemotherapy on cognitive function among ovarian cancer patients so that effective preventive and treatment strategies can be developed.

AB - Change in cognitive function is increasingly being recognized as an adverse outcome related to chemotherapy treatment. These changes need not be severe to impact patient functional ability and quality of life. The primary goal of this study was to determine if there is evidence of changes in the cognitive function domains of attention, processing speed, and response time among women with newly diagnosed advanced ovarian cancer who receive chemotherapy. Eligible patients were women diagnosed with stage III-IV epithelial ovarian or primary peritoneal cancer who had not yet received chemotherapy but who were prescribed a minimum of six cycles (courses) of chemotherapy treatment. Cognitive function was assessed by a computerized, Web-based assessment (attention, processing speed, and reaction time) and by patient self-report. Cognitive function was assessed at three time points: prior to the first course (baseline), course three, and course six. Medical records were reviewed to abstract information on chemotherapy treatment, concomitant medications, and blood test results (eg, hemoglobin, CA-125). Of the 27 eligible participants, 92% and 86% demonstrated cognitive impairments from baseline to course three and from baseline to course six of chemotherapy, respectively. Impairment was detected in two or more cognitive domains among 48% (12 of 25) and 41% (9 of 22) of participants at course three and course six of chemotherapy, respectively. This study shows evidence of decline in cognitive function among women being treated for ovarian cancer. There is a need for additional, prospective research to better understand the impact of chemotherapy on cognitive function among ovarian cancer patients so that effective preventive and treatment strategies can be developed.

UR - http://www.scopus.com/inward/record.url?scp=78751542588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751542588&partnerID=8YFLogxK

U2 - 10.1016/j.suponc.2010.09.028

DO - 10.1016/j.suponc.2010.09.028

M3 - Article

C2 - 21265392

AN - SCOPUS:78751542588

VL - 8

SP - 252

EP - 258

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 6

ER -